Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 7:04 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 897 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Once Weekly Clear all

Conditions: Erectile Dysfunction
Interventions: Shockwave Therapy, SHAM shockwave therapy; Device · Other
Lead sponsor: University of Miami; Other
Eligibility: 40 Years to 75 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: COVID-19
Interventions: Apixaban 2.5 MG, Apixaban 5MG, Aspirin, Placebo; Drug
Lead sponsor: Frank C Sciurba; Other
Eligibility: 40 Years to 80 Years
Enrollment: 657 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 71
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 51 more

Conditions: Healthy Women
Interventions: Essential Amino Acid+, Non-Calorie Placebo, High intensity Interval Training, No Exercise; Dietary Supplement · Behavioral · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 25 Years to 45 Years · Female only
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Dental Caries
Interventions: C16G2 Gel, Placebo; Drug · Other
Lead sponsor: Armata Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 135 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 10
States / cities: Imperial Beach, California • Indianapolis, Indiana • Boston, Massachusetts + 6 more

Conditions: Rheumatoid Arthritis
Interventions: Veltuzumab; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 8
States / cities: La Mesa, California • Los Angeles, California • Upland, California + 5 more

Conditions: Multiple Sclerosis
Interventions: repository corticotropin injection, Saline; Drug
Lead sponsor: University at Buffalo; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Chronic Hepatitis B
Interventions: TDF, Vesatolimod, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 9
States / cities: Los Angeles, California • Palo Alto, California • San Diego, California + 6 more

Conditions: Hepatitis C
Interventions: BMS-790052 (NS5A Replication Complex Inhibitor), Placebo matching BMS-790052, Pegylated-interferon alfa 2a, Ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 4
States / cities: San Clemente, California • Worcester, Massachusetts • Providence, Rhode Island + 1 more

Conditions: Arthritis, Rheumatoid
Interventions: LY2189102, placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 10
States / cities: Tucson, Arizona • Upland, California • Miami, Florida + 7 more

Conditions: Heart Failure
Interventions: PB1046 Injection, Placebo Injection; Drug
Lead sponsor: PhaseBio Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 5
States / cities: Anniston, Alabama • Peoria, Arizona • Daytona Beach, Florida + 2 more

Conditions: Obesity
Interventions: NNC0487-0111, Placebo (matched to NNC0487-0111); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 606 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 13
States / cities: Anniston, Alabama • Walnut Creek, California • Orlando, Florida + 9 more

Conditions: Alpha 1-Antitrypsin Deficiency, Emphysema
Interventions: SAR447537, Zemaira; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 39
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more

Conditions: PTSD - Post Traumatic Stress Disorder, Insomnia, TBI (Traumatic Brain Injury)
Interventions: Suvorexant, Placebo, Prolonged Exposure Therapy for Primary Care (PE-PC); Drug · Behavioral
Lead sponsor: Northern California Institute of Research and Education; Other
Eligibility: 18 Years to 75 Years
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: San Francisco, California

Conditions: IgA Nephropathy
Interventions: Placebo, Atacicept 25 mg, Atacicept 75 mg; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 16
States / cities: Glendale, Arizona • Chula Vista, California • Denver, Colorado + 13 more

Conditions: Systemic Sclerosis, Scleroderma
Interventions: Anifrolumab (blinded), Placebo (blinded), Anifrolumab (unblinded, open label); Combination Product · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 26
States / cities: Scottsdale, Arizona • Chula Vista, California • Los Angeles, California + 23 more

Conditions: Type 2 Diabetes, Overweight, Obesity
Interventions: Tirzepatide, Placebo; Drug · Other
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 938 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 43
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Huntington Park, California + 39 more

Conditions: Duchenne Muscular Dystrophy
Interventions: SRP-4045, Placebo; Drug
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 7 Years to 21 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 3
States / cities: Los Angeles, California • Chicago, Illinois • Baltimore, Maryland

Conditions: Rheumatoid Arthritis
Interventions: Protein, Carbohydrate (Placebo), Resistance Exercise Program; Dietary Supplement · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 60 Years to 95 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Infection
Interventions: Alendronate, Placebo, Calcium carbonate/vitamin D; Drug · Dietary Supplement
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 11 Years to 24 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 7
States / cities: Los Angeles, California • Miami, Florida • Tampa, Florida + 4 more

Conditions: Type 2 Diabetes (T2D)
Interventions: NNC0487-0111 subcutanous, Placebo (NNC0487-0111 subcutanous), NNC0487-0111 oral, Placebo (NNC0487-0111 oral); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 448 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 39
States / cities: Birmingham, Alabama • Los Angeles, California • Santa Ana, California + 30 more

Conditions: Spinal Cord Injuries
Interventions: TNM at a sham-point (AccelBand) - randomized arm, TNM at a leg point (AccelBand)- randomized arm, TNM at a leg point (AccelBand)- open-label; Device
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Current or Recent History of Atrial Fibrillation
Interventions: bucindolol hydrochloride, metoprolol succinate, Placebo oral capsule; Drug · Other
Lead sponsor: ARCA Biopharma, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 48
States / cities: Anchorage, Alaska • Phoenix, Arizona • East Palo Alto, California + 43 more

Conditions: Type 2 Diabetes Mellitus
Interventions: tirzepatide, Dulaglutide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 35
States / cities: Mobile, Alabama • Anaheim, California • Fresno, California + 30 more

Conditions: Hepatitis C
Interventions: CTS-1027, pegylated interferon, Ribavirin, Placebo; Drug
Lead sponsor: Conatus Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 45
States / cities: Birmingham, Alabama • Coronado, California • La Jolla, California + 33 more

Search by objective public record fields.

Clinical Trial of Low Intensity Shockwaves Therapy for Erectile Dysfunction Post-Radical Prostatectomy

COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80

Daily Upgrade Trial

Phase 2 Study to Evaluate the Microbiology and Safety of C16G2 Administered to Adult and Adolescent Dental Subjects

VELVET, a Dose Range Finding Trial of Veltuzumab in Subjects With Moderate to Severe Rheumatoid Arthritis

Effect of Adrenocorticotropin Injection With Weekly Interferon Beta in Patients With Relapsing Remitting Multiple Sclerosis (MS)

Study to Evaluate the Safety, Tolerability, and Efficacy of Vesatolimod in Combination With Tenofovir Disoproxil Fumarate (TDF) in Adults With Chronic Hepatitis B (CHB) Infection Who Are Currently Not Being Treated

Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C

A Safety and Pharmacokinetics Study in Participants With Rheumatoid Arthritis

Study to Assess the Safety, Tolerability and PK/PD After 4 Weekly SC Injections of PB1046 in Subjects With Stable HFrEF

AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss

Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema

Suvorexant 3 - PE-PC

Efficacy and Safety of Atacicept in IgA Nephropathy

Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight

Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients

The PRESS RA: Protein and Resistance Exercise Supplementation Study for Rheumatoid Arthritis

Safety and Effectiveness of Alendronate for Bone Mineral Density in HIV-infected Children and Adolescents

A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes

Efficacy of a Wearable Noninvasive Neuromodulation Device

Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus

Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders